PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-43.54%
Cash & equivalents declining -43.54% while CRVO's grows 0.00%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-43.54%
Both CRVO and the company show zero Cash + Short-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-43.54%
Below half of CRVO's 11796.42%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-43.54%
Below half of CRVO's 28.31%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-14.50%
Above 1.5x CRVO's -8.31%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.61%
Similar yoy to CRVO's 9.97%. Walter Schloss sees parallel short-term liability strategies.
6.57%
Higher Long-Term Debt Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.57%
Higher Total Non-Current Liabilities Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
7.49%
Similar yoy to CRVO's 8.32%. Walter Schloss sees parallel expansions in total liabilities.
No Data
No Data available this quarter, please select a different quarter.
-3.05%
Below half CRVO's -21.72%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.62%
Below half CRVO's 181.72%. Michael Burry sees potential underperformance in building shareholder capital.
-43.54%
Below half CRVO's 28.31%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
6.57%
Less than half of CRVO's 179.78%. David Dodd sees less overall debt expansion vs. competitor.
8.17%
Less than half of CRVO's 119.74%. David Dodd sees better deleveraging or stronger cash buildup than competitor.